Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Sauer T, Hänel M, Herbst R, Schäfer-Eckart K, Noppeney R, Jost E, Brümmendorf TH, Krause S, Kunzmann V, Einsele H, Scholl S, Hochhaus A, Fransecky LR, Kaufmann M, Neubauer A, Niemann D, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Klein S, Von Bonin M, Middeke JM, Thiede C, Stoelzel F, Schetelig J, Ehninger G, Baldus CD, Müller-Tidow C, Platzbecker U, Serve H, Bornhäuser M (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Blood American Society of Hematology

Book Volume: 134

Pages Range: 13-

Journal Issue: 1

DOI: 10.1182/blood-2019-123717

Abstract

DISCLOSURES: Krämer: Daiichi-Sankyo: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer: Research Funding; BMS: Research Funding; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Hänel:Roche: Honoraria; Amgen: Honoraria; Celgene: Other: advisory board; Novartis: Honoraria; Takeda: Other: advisory board. Jost:Daiichi: Honoraria; Sanofi: Honoraria; Gilead: Other: travel grants; Jazz Pharmaceuticals: Honoraria. Brümmendorf:Merck: Consultancy; Janssen: Consultancy; Novartis: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; University Hospital of the RWTH Aachen: Employment; Ariad: Consultancy. Krause:Siemens: Research Funding; Takeda: Honoraria; MSD: Honoraria; Gilead: Other: travel; Celgene Corporation: Other: Travel. Scholl:Novartis: Other: Project funding; Pfizer: Other: Advisory boards; Gilead: Other: Project funding; Daiichi Sankyo: Other: Advisory boards; AbbVie: Other: Advisory boards. Hochhaus:Pfizer: Research Funding; Novartis: Research Funding; BMS: Research Funding; Incyte: Research Funding; MSD: Research Funding. Kiani:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Middeke:Sanofi: Research Funding, Speakers Bureau; Roche: Speakers Bureau; AbbVie: Consultancy, Speakers Bureau; Gilead: Consultancy; Janssen: Consultancy, Speakers Bureau; MSD: Consultancy. Thiede:AgenDix GmbH: Employment, Equity Ownership; Novartis: Research Funding, Speakers Bureau; Bayer: Research Funding; Daiichi-Sankyo: Speakers Bureau. Stoelzel:JAZZ Pharmaceuticals: Consultancy; Neovii: Other: Travel funding; Shire: Consultancy, Other: Travel funding. Platzbecker:Celgene: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding.

Authors with CRIS profile

Stefan Krause Department of Medicine 5 – Haematology and Oncology

Involved external institutions

Klinikum Chemnitz DE Germany (DE) Universitätsklinikum Aachen (UKA) DE Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) DE Germany (DE) Philipps-Universität Marburg DE Germany (DE) Technische Universität Dresden DE Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) Klinikum Nürnberg DE Germany (DE) Universitätsklinikum Leipzig DE Germany (DE) Fraunhofer-Institut für Biomedizinische Technik (IBMT) / Fraunhofer Institute for Biomedical Engineering DE Germany (DE) Universitätsklinikum Münster DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) DIAKO Evangelisches Diakonie-Krankenhaus gGmbH DE Germany (DE) Klinikum Bielefeld DE Germany (DE) Goethe-Universität Frankfurt am Main DE Germany (DE) Universitätsklinikum Halle (Saale) DE Germany (DE) St. Bernward Krankenhaus DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Jena DE Germany (DE) Robert-Bosch-Krankenhaus DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) DE Germany (DE) Universitätsklinikum Mannheim DE Germany (DE) Klinikum Bayreuth DE Germany (DE) Rems-Murr-Kliniken DE Germany (DE)

How to cite

APA:

Röllig, C., Kramer, M., Schliemann, C., Mikesch, J.H., Steffen, B., Krämer, A.,... Bornhäuser, M. (2019). Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 134(1), 13-. https://doi.org/10.1182/blood-2019-123717

MLA:

Röllig, Christoph, et al. "Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia." Blood 134.1 (2019): 13-.

BibTeX: Download